V
Vivo Capital, LLC
+ HoldingETNB
+15.70%
3M Return
$14.840
0.000 (0.00%)終値時点
Loading chart…
- High
- 14.870
- Open
- 14.830
- VWAP
- 14.84
- Vol
- 55.65M
- Mkt Cap
- 741.82M
- Low
- 14.820
- Amount
- 825.96M
- EV/EBITDA, TTM
- -2.85
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.
バリュエーション指標
The current forward P/E ratio for 89Bio Inc (ETNB) is -3.58, compared to its 5-year average forward P/E of -4.14.
Whales holding ETNB
イベントタイムライン
ニュース
4.010-31BenzingaCantor Fitzgerald Halts Overweight Rating for 89bio
7.010-16PRnewswireSHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders
7.010-16GlobenewswireBRODSKY & SMITH INVESTOR ALERT: Updates on Ongoing Investigations for 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), and Dayforce, Inc. (NYSE - DAY)
7.010-08GlobenewswireSHAREHOLDER RIGHTS NOTICE: Halper Sadeh LLC Probes DAY, BRNS, ETNB, VRNT for Shareholder Interests
7.010-08GlobenewswireBRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), and Dayforce, Inc. (NYSE - DAY)
ETNB FAQ — answered by Alphio AI
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。